Chorionic tumors

New England Journal of Medicine

Volumn 335, Issue 23, 1996, Pages 1740-1798

  Berkowitz, Ross S ^a   Goldstein, Donald P ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CHORIONIC GONADOTROPIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; METHOTREXATE;

BIRTH DEFECT; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CHORIOCARCINOMA; CLINICAL FEATURE; CYTOGENETICS; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; HYDATIDIFORM MOLE; HYSTERECTOMY; KARYOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TROPHOBLASTIC TUMOR;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYDATIDIFORM MOLE; NEOPLASM STAGING; PREGNANCY; RISK FACTORS; TROPHOBLASTIC NEOPLASMS; UTERINE NEOPLASMS;

EID: 0029957676     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199612053352306     Document Type: Review

References (100)

1. Berkowitz RS, Goldstein DP. The management of molar pregnancy and gestational trophoblastic tumors. In: Knapp RC, Berkowitz RS, eds. Gynecologic oncology. 2nd ed. New York: McGraw-Hill, 1993:328-38.
2. Bagshawc KD. Risks and prognostic factors in trophoblastic neoplasia. Cancer 1976;38:1373-85.
3. Jones WB. Gestational trophoblastic disease: what have we learned in the past decade? Am J Obstet Gynecol 1990;162:1286-95.
4. Lurain JR, Sciarra JJ. Study and treatment of gestational trophoblastic diseases at the John I. Brewer Trophoblastic Disease Center, 1962-1990. Eur J Gynaecol Oncol 1991;12:425-8.
5. Vassilakos P, Riotton G, Kajii T. Hydatidiform mole: two entities: a morphologic and cytogenetic study with some clinical consideration. Am J Obstet Gynecol 1977;127:167-70.
6. Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol 1978;131:665-71.
7. Idem. The syndromes of hydatidiform mole. II. Morphologic evolution of the complete and partial mole. Am J Obstet Gynecol 1978;132:20-7.
8. Montes M, Roberts D, Berkowitz R, Genest D. Prevalence and significance of implantation site trophoblastic atypia in hydatidiform moles and spontaneous abortions. Am J Clin Pathol 1996;105:411-6.
9. Kajii T, Ohama K. Androgenetic origin of hydatidiform mole. Nature 1977;268:633-4.
10. Yamashita K, Wake N, Araki T, Ichinoe K, Makoto K. Human lymphocyte antigen expression in hydatidiform mole: androgenesis following fertilization by a haploid sperm. Am J Obstet Gynecol 1979;135:597-600.
11. Pattillo RA, Sasaki S, Katayama KP, Roesler M, Mattingly RF. Genesis of 46,XY hydatidiform mole. Am J Obstet Gynecol 1981;141:104-5.
12. Azuma C, Saji F, Tokugawa Y, et al. Application of gene amplification by polymerase chain reaction to genetic analysis of molar mitochondrial DNA: the detection of anuclear empty ovum as the cause of complete mole. Gynecol Oncol 1991;40:29-33.
13. Lawler SD, Fisher RA, Dent J. A prospective genetic study of complete and partial hydatidiform moles. Am J Obstet Gynecol 1991;164:1270-7.
14. Lage JM, Mark SD, Roberts DJ, Goldstein DP, Bernstein MR, Berkowitz RS. A flow cytometric study of 137 fresh hydropic placentas: correlation between types of hydatidiform moles and nuclear DNA ploidy. Obstet Gynecol 1992;79:403-10.
15. Doshi N, Surti U, Szulman AE. Morphologic anomalies in triploid liveborn fetuses. Hum Pathol 1983;14:716-23.
16. Bracken MB. Incidence and aetiology of hydatidiform mole: an epidemiological review. Br J Obstet Gynaecol 1987;94:1123-35.
17. Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med 1994;39:155-62.
18. Jeffers MD, O'Dwyer P, Curran B, Leader M, Gillan JE. Partial hydatidiform mole: a common but underdiagnosed condition: a 3-year retrospective clinicopathological and DNA flow cytometric analysis. Int J Gynecol Pathol 1993;12:315-23.
19. Parazzini F, La Vecchia C, Mangili G, et al. Dietary factors and risk of trophoblastic disease. Am J Obstet Gynecol 1988;158:93-9.
20. Berkowitz RS, Cramer DW, Bernstein MR, Cassells S, Driscoll SG, Goldstein DP. Risk factors for complete molar pregnancy from a case-control study. Am J Obstet Gynecol 1985;152:1016-20.
21. O'Toole BA, Fradkin R, Warkang J, Wilson JG, Mann GV. Vitamin A deficiency and reproduction in rhesus monkeys. J Nutr 1974;104:1513-24.
22. McLaren DS. Present knowledge of the role of vitamin A in health and disease. Trans R Soc Trop Med Hyg 1966;60:436-62.
23. Parazzini F, La Vecchia C, Pampallona S. Parental age and risk of complete and partial hydatidiform mole. Br J Obstet Gynaecol 1986;93:582-5.
24. Parazzini F, Mangili G, La Vecchia C, Negri E, Bocciolone L, Fasoli M. Risk factors for gestational trophoblastic disease: a separate analysis of complete and partial hydatiform moles. Obstet Gynecol 1991;78:1039-45.
25. Acaia B, Parazzini F, La Vecchia C, Ricciardiello O, Fedele L, Battista Candiani G. Increased frequency of complete hydatidiform mole in women with repeated abortion. Gynecol Oncol 1988;31:310-4.
26. Berkowitz RS, Bernstein MR, Harlow BL, et al. Case-control study of risk factors for partial molar pregnancy. Am J Obstet Gynecol 1995;173: 788-94.
27. The diagnosis and management of molar pregnancy. In: Goldstein DP, Berkowitz RS. Gestational trophoblastic neoplasms: clinical principles of diagnosis and management. Vol. 14 of Major problems in obstetrics and gynecology. Philadelphia: W.B. Saunders, 1982:143-75.
28. Curry SL, Hammond CB, Tyrey L, Creasman WT, Parker RT. Hydatidiform mole: diagnosis, management, and long-term follow-up of 347 patients. Obstet Gynecol 1975;45:1-8.
29. Kohorn EI. Molar pregnancy: presentation and diagnosis. Clin Obstet Gynecol 1984;27:181-91.
30. Santos-Ramos R, Forney JP, Schwarz BE. Sonographic findings and clinical correlations in molar pregnancy. Obstet Gynecol 1980;56:186-92.
31. Osathanondh R, Berkowitz RS, de Cholnoky C, Smith BS, Goldstein DP, Tyson JE. Hormonal measurements in patients with theca lutein cysts and gestational trophoblastic disease. J Reprod Med 1986;31:179-83.
32. Berkowitz RS, Goldstein DP. Pathogenesis of gestational trophoblastic neoplasms. Pathobiol Annu 1981;11:391-411.
33. Soto-Wright V, Bernstein M, Goldstein DP, Berkowitz RS. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol 1995;86:775-9.
34. Paradinas FJ, Browne P, Fisher RA, Foskett M, Bagshawe KD, Newlands E. A clinical, histopathological and flow cytometric study of 149 complete moles, 146 partial moles and 107 non-molar hydropic abortions. Histopathology 1996;28:101-9.
35. Berkowitz RS, Goldstein DP, Bernstein MR. Natural history of partial molar pregnancy. Obstet Gynecol 1985;66:677-81.
36. Szulman AE, Surti U. The clinicopathologic profile of the partial hydatidiform mole. Obstet Gynecol 1982;59:597-602.
37. Czernobilsky B, Barash A, Lancet M. Partial moles: a clinicopathologic study of 25 cases. Obstet Gynecol 1982;59:75-7.
38. Munyer TP, Callen PW, Filly RA, Braga CA, Jones HW III. Further observations on the sonographic spectrum of gestational trophoblastic diseases. J Clin Ultrasound 1981;9:349-58.
39. Romero R, Morgan JG, Kohorn EI, Kadar N, Taylor KJ, Hobbins JC. New criteria for the diagnosis of gestational trophoblastic disease. Obstet Gynecol 1985;66:553-8.
40. Fine C., Bundy AL, Berkowitz RS, Boswell SB, Berezin AF, Doubilet PM. Sonographic diagnosis of partial hydatidiform mole. Obstet Gynecol 1989;73:414-8.
41. Goldstein DP, Berkowitz RS. Current management of complete and partial molar pregnancy. J Reprod Med 1994;39:139-46.
42. Genest DR, LaBorde O, Berkowitz RS, Goldstein DP, Bernstein MR, Lage J. A clinicopathologic study of 153 cases of complete hydatidiform mole (1980-1990): histologic grade lacks prognostic significance. Obstet Gynecol 1991;78:402-9.
43. Stone M, Dent J, Kardana A, Bagshawe KD. Relationship of oral contraception to development of trophoblastic tumour after evacuation of a hydatidiform mole. Br J Obstet Gynaecol 1976;83:913-6.
44. Berkowitz RS, Goldstein DP, Marean AR, Bernstein MR. Oral contraceptives and postmolar trophoblastic disease. Obstet Gynecol 1981;58: 474-7.
45. Curry SL, Schlaerth JB, Kohorn EI, et al. Hormonal contraception and trophoblastic sequelae after hydatidiform mole (a Gynecologic Oncology Group Study). Am J Obstet Gynecol 1989;160:805-11.
46. Kohorn EI. Hydatidiform mole and gestational trophoblastic disease in southern Connecticut. Obstet Gynecol 1982;59:78-84.
47. Lurain JR, Brewer JI, Torok EE, Halpern B. Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol 1983;145: 591-5.
48. Morrow CP, Kletzky OA, Disaia PJ, Townsend DE, Mishell DR, Nakamura RM. Clinical and laboratory correlates of molar pregnancy and trophoblastic disease. Am J Obstet Gynecol 1977;128:424-30.
49. Morrow CP. Postmolar trophoblastic disease: diagnosis, management, and prognosis. Clin Obstet Gynecol 1984;27:211-20.
50. Xia ZF, Song HZ, Tang MY. Risk of malignancy and prognosis using a provisional scoring system in hydatidiform mole. Chin Med J (Engl) 1980;93:605-12.
51. Tow WSH. The influence of the primary treatment of hydatidiform mole on its subsequent course. J Obstet Gynaecol Br Commonw 1966;73: 544-52.
52. Tsukamoto N, Iwasaka T, Kashimura Y, Uchino H, Kashimura M, Matsuyama T. Gestational trophoblastic disease in women aged 50 or more. Gynecol Oncol 1985;20:53-61.
53. Parazzini F, Mangili G, Belloni C, La Vecchia C, Liati P, Marabini R. The problem of identification of prognostic factors for persistent trophoblastic disease. Gynecol Oncol 1988;30:57-62.
54. Berkowitz RS, Bernstein MR, Laborde O, Goldstein DP. Subsequent pregnancy experience in patients with gestational trophoblastic disease: New England Trophoblastic Disease Center, 1965-1992. J Reprod Med 1994;39:228-32.
55. Goldstein DP, Berkowitz RS. Prophylactic chemotherapy of complete molar pregnancy. Semin Oncol 1995;22:157-60.
56. Kashimura Y, Kashimura M, Sugimori H, et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow-up. Cancer 1986;58: 624-9.
57. Fasoli M, Ratti E, Franceschi S, La Vecchia C, Pecorclli S, Mangioni C. Management of gestational trophoblastic disease: results of a cooperative study. Obstet Gynecol 1982;60:205-9.
58. Goldstein DP Prophylactic chemotherapy of patients with molar pregnancy. Obstet Gynecol 1971;38:817-22.
59. Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol 1986;67:690-4.
60. Berkowitz RS, Goldstein DP, DuBeshter B, Bernstein MR. Management of complete molar pregnancy. J Reprod Med 1987;32:634-9.
61. Goto S, Yamada A, Ishizuka T, Tomoda Y. Development of postmolar trophoblastic disease after partial molar pregnancy. Gynecol Oncol 1993; 48:165-70.
62. Bolis G, Belloni C, Bonazzi C, et al. Analysis of 309 cases after hydatidiform mole: different follow-up program according to biologic behavior. Tumori 1988;74:93-6.
63. Bagshawe KD, Lawler SD, Paradinas FJ, Dent J, Brown P, Boxer GM. Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole. Lancet 1990;335:1074-6.
64. Wong LC, Ma HK. The syndrome of partial mole. Arch Gynecol 1984;234:161-6.
65. Rice LW, Berkowitz RS, Lage JM, Goldstein DP, Bernstein MR. Persistent gestational trophoblastic tumor after partial hydatidiform mole. Gynecol Oncol 1990;36:358-62.
66. Scully RE, Young RH. Trophoblastic pseudotumor: a reappraisal. Am J Surg Pathol 1981;5:75-6.
67. Finkler NJ, Berkowitz RS, Driscoll SG, Goldstein DP, Bernstein MR. Clinical experience with placental site trophoblastic tumors at the New England Trophoblastic Disease Center. Obstet Gynecol 1988;71:854-7.
68. Kelly MP, Rustin GJS, Ivory C, Phillips P, Bagshawe KD. Respiratory failure due to choriocarcinoma: a study of 103 dyspneic patients. Gynecol Oncol 1990;38:149-54.
69. Bakri YN, Berkowitz RS, Khan J, Goldstein DP, von Sinner W, Jabbar FA. Pulmonary metastases of gestational trophoblastic tumor: risk factors for early respiratory failure. J Reprod Med 1994;39:175-8.
70. Gestational trophoblastic diseases: report of a WHO scientific group. WHO Tech Rep Ser 1983;692:51.
71. Athanassiou A, Begent RHJ, Newlands ES, Parker D, Rustin GJ, Bagshawe KD. Central nervous system metastases of choriocarcinoma: 23 years' experience at Charing Cross Hospital. Cancer 1983;52:1728-35.
72. Bakri Y, Berkowitz RS, Goldstein DP, et al. Brain metastases of gestational trophoblastic tumor. J Reprod Med 1994;39:179-84.
73. Bagshawe KD, Harland S. Immunodiagnosis and monitoring of gonadotrophin-producing metastases in the central nervous system. Cancer 1976;38:112-8.
74. Berkowitz RS, Osathanondh R, Goldstein DP, Martin PM, Mallampati SR, Datta S. Cerebrospinal fluid human chorionic gonadotropin levels in normal pregnancy and choriocarcinoma. Surg Gynecol Obstet 1981;153: 687-9.
75. Dobkin GR, Berkowitz RS, Goldstein DP, Bernstein MR, Doubilet PM. Duplex ultrasonography for persistent gestational trophoblastic tumor. J Reprod Med 1991;36:14-6.
76. Mutch DG, Soper JT, Baker ME, et al. Role of computed axial tomography of the chest in staging patients with nonmetastatic gestational trophoblastic disease. Obstet Gynecol 1986;68:348-52.
77. DuBeshter B, Berkowitz RS, Goldstein DP, Cramer DW, Bernstein MR. Metastatic gestational trophoblastic disease: experience at the New England Trophoblastic Disease Center, 1965 to 1985. Obstet Gynecol 1987;69:390-5.
78. Dubuc-Lissoir J, Sweizig S, Schlaerth JB, Morrow CP. Metastatic gestational trophoblastic disease: a comparison of prognostic classification systems. Gynecol Oncol 1992;45:40-5.
79. Ayhan A, Yapar EG, Deren O, Kisnisci H. Remission rates and significance of prognostic factors in gestational trophoblastic tumors. J Reprod Med 1992;37:461-5.
80. Soper JT, Clarke-Pearson DL, Bcrchuck A, Rodriguez G, Hammond CB. 5-Day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol 1994;54:76-9.
81. Soper JT. Surgical therapy for gestational trophoblastic disease. J Reprod Med 1994;39:168-74.
82. Weed JC Jr, Hammond CB. Cerebral metastatic choriocarcinoma: intensive therapy and prognosis. Obstet Gynecol 1980;55:89-94.
83. Yordan EL Jr, Schlaerth J, Gaddis O Jr, Morrow CP. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol 1987;69:627-30.
84. Rustin GJS, Newlands ES, Begent RHJ, Dent J, Bagshawe KD. Weekly alternating etoposide, methotrexate, actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 1989;7:900-3.
85. Homesley HD. Development of single-agent chemotherapy regimens for gestational trophoblastic disease. J Reprod Med 1994;39:185-92.
86. Kohom EI. Single-agent chemotherapy for nonmetastatic gestational trophoblastic neoplasia: perspectives for the 21st century after three decades of use. J Reprod Med 1991;36:49-55.
87. Berkowitz RS, Goldstein DP, Bernstein MR. Ten years' experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986;23:111-8.
88. Schlaerth JB, Morrow CP, Nalick RH, Gaddis O Jr. Single-dose actinomycin D in the treatment of postmolar trophoblastic disease. Gynecol Oncol 1984;19:53-6.
89. Gordon AN, Gershenson DM, Copeland LJ, Stringer CA, Morris M, Wharton JT. High-risk metastatic gestational trophoblastic disease: further stratification into two clinical entities. Gynecol Oncol 1989;34:54-6.
90. Mortakis AE, Braga CA. "Poor prognosis" metastatic gestational trophoblastic disease: the prognostic significance of the scoring system in predicting chemotherapy failures. Obstet Gynecol 1990;76:272-7.
91. Curry SL, Blessing JA, DiSaia PJ, Soper JT, Twiggs LB. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Obstet Gynecol 1989;73:357-62.
92. Wong LC, Choo YC, Ma HK. Primary oral etoposide therapy in gestational trophoblastic disease: an update. Cancer 1986;58:14-7.
93. Bolis G, Bonazzi C, Landoni F, et al. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol 1988;31:439-44.
94. Newlands ES, Bagshawe KD, Begent RHJ, Rustin GJ, Holden L. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol 1991;98:550-7.
95. Schink JC, Singh DK, Rademaker AW, Miller DS, Lurain JR. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease. Obstet Gynecol 1992;80:817-20.
96. Soper JT, Evans AC, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB. Alternating weekly chemotherapy with etoposide-methotrexate dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Obstet Gynecol 1994;83:113-7
97. Azab M, Droz JP, Theodore C, Wolff JP, Amiel JL. Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors. Cancer 1989;64:1829-32.
98. DuBeshter B, Berkowitz RS, Goldstein DP, Bernstein MR. Vinblastine, cisplatin and bleomycin as salvage therapy for refractory high-risk metastatic gestational trophoblastic disease. J Reprod Med 1989;34:189-92.
99. Rustin GJS, Rustin F, Dent J, Booth M, Salt S, Bagshawe KD. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. N Engl J Med 1983;308:473-6.
100. Rustin GJS, Newlands ES, Lutz JM, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996;14: 2769-73.